Literature DB >> 20713353

Phosphorylation and activation of androgen receptor by Aurora-A.

Shao-Kun Shu1, Qiyuan Liu, Domenico Coppola, Jin Q Cheng.   

Abstract

Aurora-A kinase is frequently overexpressed/activated in various types of human malignancy, including prostate cancer. In this study, we demonstrate elevated levels of Aurora-A in androgen-refractory LNCaP-RF but not androgen-sensitive LNCaP cells, which prompted us to examine whether Aurora-A regulates the androgen receptor (AR) and whether elevated Aurora-A is involved in androgen-independent cell growth. We show that ectopic expression of Aurora-A induces AR transactivation activity in the presence and absence of androgen. Aurora-A interacts with AR and phosphorylates AR at Thr(282) and Ser(293) in vitro and in vivo. Aurora-A induces AR transactivation activity in a phosphorylation-dependent manner. Ectopic expression of Aurora-A in LNCaP cells induces prostate-specific antigen expression and cell survival, whereas knockdown of Aurora-A sensitizes LNCaP-RF cells to apoptosis and cell growth arrest. These data indicate that AR is a substrate of Aurora-A and that elevated Aurora-A could contribute to androgen-independent cell growth by phosphorylation and activation of AR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713353      PMCID: PMC2963369          DOI: 10.1074/jbc.M110.121129

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  Coactivator and corepressor complexes in nuclear receptor function.

Authors:  L Xu; C K Glass; M G Rosenfeld
Journal:  Curr Opin Genet Dev       Date:  1999-04       Impact factor: 5.578

Review 2.  Aurora-A - a guardian of poles.

Authors:  Tomotoshi Marumoto; Dongwei Zhang; Hideyuki Saya
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

Review 3.  The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways.

Authors:  Joanne Edwards; John M S Bartlett
Journal:  BJU Int       Date:  2005-06       Impact factor: 5.588

Review 4.  The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

Authors:  Joanne Edwards; John M S Bartlett
Journal:  BJU Int       Date:  2005-06       Impact factor: 5.588

5.  A new human prostate carcinoma cell line, 22Rv1.

Authors:  R M Sramkoski; T G Pretlow; J M Giaconia; T P Pretlow; S Schwartz; M S Sy; S R Marengo; J S Rhim; D Zhang; J W Jacobberger
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

Review 6.  Androgen receptor cross-talk with cell signalling pathways.

Authors:  Zoran Culig
Journal:  Growth Factors       Date:  2004-09       Impact factor: 2.511

7.  The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

Authors:  Eiji Tanaka; Yosuke Hashimoto; Tetsuo Ito; Tomoyuki Okumura; Takatsugu Kan; Go Watanabe; Masayuki Imamura; Johji Inazawa; Yutaka Shimada
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

8.  Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215.

Authors:  Qiyuan Liu; Satoshi Kaneko; Lin Yang; Richard I Feldman; Santo V Nicosia; Jiandong Chen; Jin Q Cheng
Journal:  J Biol Chem       Date:  2004-10-06       Impact factor: 5.157

9.  Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.

Authors:  Hideaki Miyake; Mototsugu Muramaki; Toshifumi Kurahashi; Atsushi Takenaka; Masato Fujisawa
Journal:  Urol Oncol       Date:  2008-10-10       Impact factor: 3.498

10.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.

Authors:  H Zhou; J Kuang; L Zhong; W L Kuo; J W Gray; A Sahin; B R Brinkley; S Sen
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

View more
  20 in total

1.  Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Authors:  William H Lagarde; Amanda J Blackwelder; John T Minges; Andrew T Hnat; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

2.  A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells.

Authors:  Karishma S Amin; Shankar Jagadeesh; Gakul Baishya; Paruchuri G Rao; Nabin C Barua; Samir Bhattacharya; Partha P Banerjee
Journal:  Mol Cancer Ther       Date:  2013-11-20       Impact factor: 6.261

3.  Kinase modulation of androgen receptor signaling: implications for prostate cancer.

Authors:  Kalpit Shah; Neil A Bradbury
Journal:  Cancer Cell Microenviron       Date:  2015-11-19

4.  A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.

Authors:  Jianqing Lin; Sheel A Patel; Ashwin R Sama; Jean H Hoffman-Censits; Brooke Kennedy; Deborah Kilpatrick; Zhong Ye; Hushan Yang; Zhaomei Mu; Benjamin Leiby; Nancy Lewis; Massimo Cristofanilli; William Kevin Kelly
Journal:  Oncologist       Date:  2016-10-24

Review 5.  Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.

Authors:  Kristin R Lamont; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2011-03-24

Review 6.  Androgen receptor phosphorylation: biological context and functional consequences.

Authors:  Yulia Koryakina; Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-01-14       Impact factor: 5.678

Review 7.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

8.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Authors:  Ana M Aparicio; Li Shen; Elsa Li Ning Tapia; Jing-Fang Lu; Hsiang-Chun Chen; Jiexin Zhang; Guanglin Wu; Xuemei Wang; Patricia Troncoso; Paul Corn; Timothy C Thompson; Bradley Broom; Keith Baggerly; Sankar N Maity; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

9.  p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).

Authors:  Tong Liu; Yang Li; Hui Gu; Ge Zhu; Jiabin Li; Liu Cao; Feng Li
Journal:  J Biol Chem       Date:  2012-11-06       Impact factor: 5.157

Review 10.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.